Role of Reactive Oxygen Species in Endothelin-Induced Hypertension

Hypertension

Volumn 42, Issue 4, 2003, Pages 806-810

  Sedeek, Mona H ^a   Llinas, Maria T ^a   Drummond, Heather ^a   Fortepiani, Lourdes ^a   Abram, Sean R ^a   Alexander, Barbara T ^a   Reckelhoff, Jane F ^a   Granger, Joey P ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Anions; Endothelin; Hemodynamics; Hypertension, chronic; Vasoconstriction

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ENDOTHELIN; ENDOTHELIN 1; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; TEMPOL; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY PLASMA FLOW; KIDNEY VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; URINARY EXCRETION; VASCULAR RING; VASOCONSTRICTION;

ANIMALS; CELLS, CULTURED; CHRONIC DISEASE; CYCLIC N-OXIDES; DINOPROST; ENDOTHELIN-1; F2-ISOPROSTANES; FREE RADICAL SCAVENGERS; HEMODYNAMIC PROCESSES; HYPERTENSION; KIDNEY; MALE; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; SPIN LABELS; SUPEROXIDES; THIOBARBITURIC ACID REACTIVE SUBSTANCES; VASOCONSTRICTOR AGENTS;

EID: 0141928153     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/01.HYP.0000084372.91932.BA     Document Type: Article

References (23)

1. Rubany GM, Polokoff MA. Endothelin: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev. 1994; 46: 325-415.
2. Mortensen LH, Pawloski CM, Kanagy NL, Fink GD. Chronic hypertension produced by infusion of endothelin in rats. Hypertension. 1990; 15: 729-733.
3. Wilkins FC Jr, Alberola A, Mizelle HL, Opgenorth TJ, Granger JP. Systemic hemodynamics and renal function during long-term pathophysiological increases in circulating endothelin. Am J Physiol. 1995; 268: 375-381.
4. Badr KF, Murray JJ, Breyer MD, Takahashi K, Inagami T, Harris RC. Mesangial cell, glomerular and renal vascular responses to endothelin in the rat kidney: elucidation of signal transduction pathways. J Clin Invest. 1989; 83: 336-334.
5. − formation. Nephrol Dial Transplant. 2000; 15: 339-346.
6. Diederich D, Skopec J, Diederich A, Dai FX. Cyclosporine produces endothelial dysfunction by increased production of superoxide. Hypertension. 1994; 23: 957-961.
7. Kassab S, Miller MT, Hester R, Novak J, Granger JP. Systemic hemodynamics and regional blood flow during chronic nitric oxide synthesis inhibition in pregnant rats. Hypertension. 1998; 31: 315-320.
8. Alexander BT, Miller MT, Kassab S, Novak J, Reckelhoff JF, Kruckeberg WC, Granger JP. Differential expression of renal nitric oxide synthase isoforms during pregnancy in rats. Hypertension. 1999; 33: 435-439.
9. Dobrian AD, Davies MJ, Schriver SD, Lauterio TJ, Prewitt RL. Oxidative stress in a rat model of obesity-induced hypertension. Hypertension. 2001; 37: 554-560.
10. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurements with the folin phenol reagent. J Biol Chem. 1951; 193: 265-275.
11. Schnackenberg CG, Wilcox CS. Two-week administration of tempol attenuates both hypertension and renal excretion of 8-Iso prostaglandin F2 alpha. Hypertension. 1999; 33: 424-428.
12. Wedgwood S, Dettman R W, Black SM. ET-1 stimulates pulmonary arterial smooth muscle cell proliferation via induction of reactive oxygen species. Am J Physiol Lung Cell Mol Physiol. 2001; 281: 1058-1067.
13. Schiffrin E. Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens. 2001; 14: 83S-89S.
14. Lerman LO, Nath KA, Rodriguez-Porcel M, Krier JD, Schwartz RS, Napoli C, Romero JC. Increased oxidative stress in experimental renovascular hypertension. Hypertension. 2001; 37: 541-546.
15. Haas JA, Krier JD, Bolterman RJ, Juncos LA, Romero JC. Low-dose angiotensin II increases free isoprostane levels in plasma. Hypertension. 1999; 34: 983-986.
16. Kato T, Kassab S, Wilkins FC, Kirchner K, Keiser J, Granger JP. Endothelin antagonist improve renal function in spontaneously hypertensive rats. Hypertension. 1995; 25: 883-887.
17. Kassab S, Novak J, Miller T, Kirchner KA, Granger JP. Cardiovascular and renal actions of endothelin receptor antagonism in Dahl salt-sensitive hypertension. Hypertension. 1997; 30: 682-686.
18. Alexander BT, Cockrell KL, Herrington JN, Granger JP. Enhanced renal expression of preproendothelin mRNA during chronic angiotensin II hypertension. Am J Physiol. 2001; 280: R1388-R1392.
19. Alexander BT, Rinewalt AN, Cockrell KL, Bennett WA, Granger JP. Endothelin-A receptor blockade attenuates the hypertension in response to chronic reductions in uterine perfusion pressure. Hypertension. 2001; 37: 485-489.
20. Granger JP, Alexander BT, Bennett WA, Khalil RA. Pathophysiology of pregnancy-induced hypertension. Am J Hypertens. 2001; 14: S178-S185.
21. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest. 1997; 100: 2153-2157.
22. Fukui T, Ishizaka N, Rajagopalan S, Laursen JB, Capers Q, Taylor WR, Harrison DG, Hector de Leon, Wilcox JN, Griendling KK. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res. 1997; 80: 45-51.
23. Heitzer T, Wenzel U, Hink U, Krollner D, Skatchkov M, Stahl RA, MacHarzina R, Brasen JH, Meinertz T, Munzel T. Increased NAD(P)H oxidase-mediated superoxide production in renovascular hypertension: evidence for an involvement of protein kinase C. Kidney Int. 1999; 55: 252-260.